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ARTICLE
Translational Therapeutics
Tumour-reactive T cell subsets in the microenvironment of
ovarian cancer
Marie Christine Wulff Westergaard1, Rikke Andersen1,2, Chloé Chong3,4, Julie Westerlin Kjeldsen1,2, Magnus Pedersen1,2,
Christina Friese1, Thomas Hasselager5, Henrik Lajer6, George Coukos3,4, Michal Bassani-Sternberg3,4, Marco Donia1,2 and
Inge Marie Svane1,2
BACKGROUND: Solid malignancies are frequently inﬁltrated with T cells. The success of adoptive cell transfer (ACT) with expanded
tumour-inﬁltrating lymphocytes (TILs) in melanoma warrants its testing in other cancer types. In this preclinical study, we
investigated whether clinical-grade TILs could be manufactured from ovarian cancer (OC) tumour specimens.
METHODS: Thirty-four tumour specimens were obtained from 33 individual patients with OC. TILs were analysed for phenotype,
antigen speciﬁcity and functionality.
RESULTS: Minimally expanded TILs (Young TILs) were successfully established from all patients. Young TILs contained a high
frequency of CD3+ cells with a variable CD4/CD8 ratio. TILs could be expanded to clinical numbers. Importantly, recognition of
autologous tumour cells was demonstrated in TILs in >50% of the patients. We conﬁrmed with mass spectrometry the presentation
of multiple tumour antigens, including peptides derived from the cancer-testis antigen GAGE, which could be recognised by
antigen-speciﬁc TILs. Antigen-speciﬁc TILs could be isolated and further expanded in vitro.
CONCLUSION: These ﬁndings support the hypothesis that patients with OC can beneﬁt from ACT with TILs and led to the initiation
of a pilot clinical trial at our institution .
TRIAL REGISTRATION: clinicaltrials.gov: NCT02482090.
British Journal of Cancer (2019) 120:424–434; https://doi.org/10.1038/s41416-019-0384-y
INTRODUCTION
The density of intratumoural inﬁltration with T cells has been
associated with improved survival in virtually all forms of solid
tumours evaluated.1–4 In fact, the natural inﬁltrates of solid tumours
may contain T cells targeting several types of tumour antigens,
including those derived from tumour-speciﬁc mutated proteins.5,6 A
technically complex approach of personalised cancer immunotherapy
based on the isolation, in vitro expansion and reinfusion of T cells
isolated from the microenvironment of an individual patient’s tumour
metastasis, has demonstrated promising results. However, so far
current protocols of T cell expansion and patient conditioning have
only been tested in a few selected forms of metastatic cancer.7
The human immune system naturally generates adaptive
immune responses against ovarian cancer (OC).8–10 OC has a
moderately high mutational load on average,11 and immune
recognition of cancer mutations have previously been shown.8
Overall, OC appears to be an promising target for strategies
enhancing endogenous immune responses.12
OC is the most lethal gynaecologic malignancy. It is often
diagnosed at an advanced stage (e.g. International Federation of
Gynecology and Obstetrics (FIGO) stage III or IV), which combined
with the lack of curative medical treatment options,13 contributes
to a poor relative 5 year survival rate of 39% and 17% in stage III
and IV, respectively, for the most common epithelial carcinomas,
which comprise 85–90% of cases.14 So far immunotherapy with
checkpoint inhibitors has shown limited efﬁcacy in OC, with
response rates ranging from 6–17%.15–18 These observations
prompted us to explore whether a personalised immunotherapy
approach based on the expansion of tumour-inﬁltrating lympho-
cytes (TILs) would be feasible in patients with OC. In this study, we
isolate, expand and test the antitumour activity in vitro of TILs
obtained from a cohort of unselected patients with OC. We show
that TIL cultures can easily be generated in the laboratory and
display antitumour activities in the majority of cases. Further, we
demonstrate that tumour antigen-speciﬁc TILs can be isolated and
expanded, resulting in increased antitumour response.
PATIENTS, MATERIALS AND METHODS
Patient material
We obtained 34 metastatic (intraoperative evaluation) tumour
specimens from 33 individual patients with histologically veriﬁed
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OC. For the vast majority of the patients the cancer was in an
advanced stage (Supplementary Table 1). All surgical resections
were part of either a primary cytoreductive or an interval
debulking procedure for OC at the Department of Gynaecology,
Rigshospitalet, Copenhagen. From one patient, tumour specimens
were received twice with 16 months interval (total n= 34 samples).
Ascitic ﬂuid was collected from 11 patients. The tumour specimens
were transported to Herlev Hospital immediately after surgery and
processed within 2 h. The scientiﬁc use of the patient material was
approved by the National Committee on Health Research Ethics
(reference number H-2-2014-055).
Reagents for TILs and tumour cells
Complete medium (CM) used for culturing TILs consisted of RPMI-
1640 with GlutaMAX, 25 mM HEPES pH 7.2 (Gibco, Massachusetts,
USA), 100 U/ml penicillin (Gibco), 100 μg/ml streptomycin (Gibco)
and Fungizone® (Bristol-Myers Squibb, Middlesex, United King-
dom) 1.25 μg/ml supplemented with 10% Human AB Serum
(Sigma-Aldrich, Missouri, United States) and 6000 IU/ml of rhIL-2
(Proleukin, Novartis, Copenhagen, Denmark).
Rapid expansion medium (RM) used for the rapid expansion
protocol (REP) consisted of AIM-V medium (Gibco) and Fungizone
1.25 μg/ml supplemented with 6000 IU/ml rhIL-2.
In addition, OKT3 (anti-CD3) antibody (MACs Miltenyi Bio-
tech, Bergisch Gladbach, Germany), Pulmozyme (Roche, Basel,
Switzerland), and allogeneic peripheral blood mononuclear cells
(PBMCs) (or feeder cells) obtained from buffy coats from healthy
donors are used in the REP.
R10 medium used for culturing tumour cells consisted of RPMI-
1640 with GlutaMAX, 25mM HEPES pH 7.2, 100 U/ml penicillin,
100 μg/ml streptomycin and foetal bovine serum (FBS) (Gibco). In
addition, Solu-Cortef (hydrocortisone sodium succinate) (the local
hospital pharmacy) 500 ng/ml was added to R10, the ﬁrst month
of establishing the tumour cell line (TCL).
Enzyme solution used for the digestion of tumour fragments
consisted of RPMI-1640 with GlutaMAX, 25 mM HEPES pH 7.2, 100
U/ml penicillin, 100 μg/ml streptomycin, 1 mg/ml collagenase
(Sigma-Aldrich) and 0.0125 mg/ml Pulmozyme (Roche).
Manufacturing of TILs
Tumour tissue was isolated from the surrounding tissue and cut
into 1–3mm3 fragments with a scalpel. Fragments were
extensively washed with phosphate-buffered saline (PBS) before
plating to minimise the risk of contaminating TIL cultures with
peripheral blood. Tumour fragments were plated in individual
wells in a 24-well culture plate with 2 ml CM. Half the media was
changed three times a week. TILs were harvested when pooled TIL
micro-cultures generated from 48 fragments reached a total
number of ≥100 × 106 cells. This product, named Young TILs, had a
generation time limit within 60 days. Young TILs were further
expanded for 14 days in a small scale REP, as previously
described.19 Brieﬂy, 100,000 TILs were mixed with 20 × 106
allogenic feeder cells, OKT3 antibody and master mix media
containing 50% CM+ 50% RM with 10% inactivated human AB
serum. Young TILs generated in parallel from tumour specimens of
metastatic melanoma (MM) were used as a comparison.
Generation and validation of TCLs
TCLs were established either directly from tumour fragments, from
media used for transportation of the tumour specimens or from
enzymatically digested fresh tumour fragments, named fresh
tumour digest (FTD). In addition, single-cell suspensions of
uncultured FTDs containing all cells present in the tumour
microenvironment (TME) were cryopreserved for later use.
TCLs were validated by (1) cytospin centrifugation of the cell
suspension for morphologic evaluation and (2) formalin-ﬁxation
and parafﬁn-embedding (FFPE) followed by immunohistochem-
istry (IHC) staining for various OC markers: CA125, EpCAM, PAX8,
p16, p53, CK7, the mesothelial cell marker Calretinin and the
proliferation marker Ki67.
Selected TCLs were tested for expression of HLA class I and HLA
class II using FACS analysis. The cells were stained with either
panHLA-class I-APC, panHLA-class II-FITC or IgG1k APC and FITC
isotypes (all from BD Bioscience, New Jersey, United States). All
cells were stained with the 7ADD live/dead marker prior to analysis
with a FACS Canto II instrument (BD Biosciences, New Jersey,
United States) measuring median ﬂuorescence intensity (MFI). The
cutoff for positive expression was deﬁned as 3× isotype MFI.
All cell lines were established internally from clinical material;
thus, no testing for mycoplasma infection was done.
Immunohistochemistry
Within 2 hours after surgery, the tumour specimens were cut into
small fragments and several fragments were randomly picked for
snap freeze samples in order to represent all parts of the tumour
tissue. Five to 7 fragments were formalin ﬁxed and embedded in
parafﬁn before performing IHC. The samples were stained for
cytokeratin A for localisation of the tumour tissue among stromal
tissue. The samples were stained for the surface immune cell
markers CD45, CD4, CD8, CD20 and CD56. The stained immune
inﬁltrates were counted in three squares covering 0.201mm2 each
on every slide, using both NanoZoomer Digital Pathology (NDP.view
2) software and Fiji Image J 1.49 software. The three squares were
placed on identical spots on every slide from the same patient with
the aim to cover as much tumour tissue as possible. A consultant
pathologist from Herlev Hospital supervised all the operations.
Phenotyping of TILs
Both Young TILs and rapid expanded TILs (REP-TILs) were stained
using ﬂuorochrome-labelled monoclonal antibodies (mAb; from
BD Bioscience, unless indicated otherwise) CD3-BV510, CD4-PerCP,
CD8-BV421, CD45RA-FITC, CD45RO-PE, CCR7-PE-Cy7, CD62L-APC,
CD69-PE-Cy7, CD28-APC, CD16-FITC (Dako, Glostrup, Denmark),
CD137-PE, CD56-PE-Cy7, Gamma-Delta-TCR-PE (Biolegend, Califor-
nia, United States), LAG-3-FITC (LS Bioscience, Seattle, WA, United
States), BTLA-PE, PD-1-PE-Cy7, TIM-3-APC (eBioscience, California,
United States) and analysed with a FACS Canto II instrument (BD
Biosciences). The phenotypic subpopulations was investigated for
statistical difference using GraphPad Prism, Wilcoxon matched-
pairs signed rank test.
Evaluation of tumour reactivity
Antitumour reactivity of in vitro-expanded TILs was evaluated after
co-culture for 5 hours of the TILs with autologous FTDs (thawed
and washed twice) or autologous TCLs pretreated with interferon-
γ (IFN-γ) (100 IU/ml), Peprotech, London, United Kingdom) or left
untreated in a ratio of 3:1. Golgi plug and CD107a-BV421 were
added at the beginning of incubation. Afterward, TILs were
stained for the surface markers Near-IR Live/Dead (Life Technol-
ogies, California, United States), CD3-FITC, CD56-PE, CD8-QD605
(Life Technologies) and CD4-PerCP (Biolegend) and after overnight
ﬁxation and permeabilisation (eBioscience) further stained for
intracellular cytokines TNF-APC and IFN-γ-PE-Cy7 (all chemicals
and antibody mentioned in this paragraph are from BD bioscience
unless indicated otherwise). The TILs were analysed with FACS
Canto II (BD Bioscience). Tumour-speciﬁc TILs were deﬁned as the
frequency of T cells expressing at least one of the following T cell
functions: tumour necrosis factor alpha (TNF-α), IFN-γ or CD107a. A
speciﬁc antitumour response was deﬁned as the presence of
minimum 0.5% responding cells, with a minimum number of 50
positive events. The frequency of tumour-reactive cells in
stimulated samples was subtracted from the unstimulated
samples. 0.5% was used as a threshold for detection of tumour
reactivity. All TIL products were tested for tumour reactivity
against FTD except TILs from patient OC.TIL.03 and against
autologous TCL (available from 11 patients).
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Cytotoxicity assays
A standard Cr51 cytotoxicity assay was performed as previously
described.20 Brieﬂy, 5 × 105 tumour cells (target cells) were pulsed
with 20 μl Cr51 for 1 hour. Autologous TILs (effector cells) and
target cells were co-cultured for 4 hours and the Cr51 content of
the supernatants was measured.
Results were further validated with an impedance-based assay
(xCELLigence assay) for real-time detection of cytotoxicity of
adherent cells.21 Tumour cells were added to the wells, 20,000
cells per well. After 2 days, when tumour cells reached a conﬂuent
stage, TILs were added with a different effector:target ratios. HLA-
blocking antibodies (W6/32 and Tü39 Biolegend) were added 30
min prior to the TILs with ﬁnal concentration 20 µg/ml. The
tumour killing was monitored in real time, with the xCELLigence
instrument (ACEA Bioscience, San Diego, CA, United States).
Immunopuriﬁcation of HLA class I peptides
Immunopuriﬁcation of HLA class I peptides was performed on a
plate format using a positive pressure processor (Waters, Milford,
Massachusetts), as previously described.22 Brieﬂy, frozen cell
pellets of OC.TIL.11 (1.6 × 108 cells) were lysed for 1 hour at 4 °C
with PBS containing 0.25% sodium deoxycholate (Sigma-Aldrich),
0.2 mM iodoacetamide (Sigma-Aldrich), 1 mM EDTA, 1:200 Pro-
tease Inhibitors Cocktail (Sigma-Aldrich), 1 mM phenylmethylsul-
fonylﬂuoride (Roche), 1% octyl-beta-D glucopyranoside (Sigma-
Alrich). Lysates were cleared by centrifugation (Eppendorf
Centrifuge, Hamburg, Germany) at 4 °C at maximum speed for
50min. The plate’s wells were equilibrated before the addition of
anti-panHLA-I (W6/32) antibodies covalently cross-linked to
Protein-A Sepharose beads (Invitrogen, California, USA). The
lysates were passed through the wells by gravity ﬂow at 4 °C.
Thereafter, washes were performed with four column volumes
sequentially of 150mM, 400 nM and lastly again 150mM in 20mM
Tris-HCl pH 8, using the processor. Lastly, beads were washed with
two column volumes of 20 mM Tris-HCl pH 8.
HLA-I peptides were puriﬁed with the application of a Sep-Pak
tC18 96-well plate (Waters). The Sep-Pak plate was ﬁrst conditioned
with 80% acetonitrile (ACN, Merck) in 0.1% triﬂuoroacetic acid
(TFA, Merck, Darmstadt, Switzerland) and subsequently also with
0.1% TFA. HLA complexes and the bound peptides were directly
eluted on to the Sep-Pak plate with 500 µl 1% TFA. C18 wells were
then washed with 0.1% TFA before elution of HLA-I peptides with
28% ACN in 0.1% TFA. Recovered HLA-I peptides were dried using
vacuum centrifugation (Thermo Fisher Scientiﬁc).
Liquid chromatography-mass spectrometry analysis
Liquid chromatography-mass spectrometry (LC-MS) analysis was
performed with the nanoﬂow Ultra-HPLC Easy nLC 1200 (Thermo
Fisher Scientiﬁc, LC140) coupled online to a Q Exactive HF Orbitrap
mass spectrometer (Thermo Fischer Scientiﬁc) with a nanoelec-
trospray ion source (Sonation, PRSO-V1; Baden-Württemberg,
Germany) as previously described.22 Peptides were eluted over
125min with a gradient of 0.1% FA in 80% ACN. Data were
acquired with a data-dependent method and HCD fragmentation
at a normalised collision energy of 27%. The MS scan range was
set to 300 to 1650m/z with a resolution of 60,000 (200m/z) and an
AGC target value of 3 x 106 ions. For MS/MS, AGC target values of
1 x 105 were used with a maximum injection time of 120ms at a
set resolution of 15,000 (200m/z). In case of unassigned precursor
charge states, or charge states of four and above, no fragmenta-
tion was performed. The dynamic exclusion of precursor ions from
further selection was set for 20 s.
Identiﬁcation of tumour-associated HLA-binding peptides
We employed the MaxQuant computational proteomics platform
version 1.5.5.1 to search the peak lists against the UniProt
databases (Human, 42,148 entries, March 2017) and a ﬁle
containing 247 frequently observed contaminants. Methionine
oxidation (15.994915 Da) was set as variable modiﬁcation. The
second peptide identiﬁcation option in Andromeda was enabled.
An FDR of 0.05 and no protein FDR was set with unspeciﬁc
enzyme speciﬁcity. Possible sequence matches were restricted to
8–25 amino acids. The initial allowed mass deviation of the
precursor ion was set to 6 ppm and the maximum fragment mass
deviation was set to 20 ppm. We enabled the “match between
runs” option, which allows matching of identiﬁcations same
biological samples in a time window of 0.5 min and an initial
alignment time window of 20min. We extracted the “peptides”
MaxQuant output table and ﬁltered out peptides matching to
reverse and contaminants. For in vitro validation of immunogeni-
city, we selected 23 HLA peptides (Supplementary Table 2)
derived from known tumour-associated proteins based on
literature and tumour speciﬁcity.
Evaluation of peptide recognition
Screening for peptide recognition was carried out with IFN-γ
ELISPOT assays. Brieﬂy, nitrocellulose bottomed 96-well plates
(Merck Millipore, Søborg, Denmark) were coated overnight at
room temperature (RT) with anti-IFN-γ antibody 1-D1K (Mab-
tech, Nacka Strand, Sweden). The plates were washed six times in
PBS and blocked by X-vivo medium (Lonza, Basel, Switzerland).
The TILs were added in triplicates, 100,000 cells/well. The selected
peptides (Supplementary Table 2) was added with a ﬁnal
concentration of 5 µM alongside a negative control without
peptide and a positive control (Staphylococcus Enterotoxin B
(SEB)). After overnight incubation at 37 °C and 5% CO2, the plates
were washed in PBS and IFN-γ biotinylated secondary Ab
(Mabtech) was added followed by a further 2 hours incubation
at RT. The plates were then again washed with PBS and
Streptavidin-ALP (Mabtech) was added followed by 1 hour
incubation at RT. Finally, the plates were washed and enzyme
substrate NBT/BCIP (Mabtech) was added. The spots were counted
using the ImmunoSpot Series 2.0 Analyzer (CTL Analyzer, Bonn,
Germany). Background spots were subtracted from the peptide
spots and an ELISPOT response was deﬁned as more than 20 spots
after background subtraction.
Anti-GAGE reactivity of in vitro-expanded TILs was evaluated as
previously described in the section Evaluation of tumour reactivity,
though the TILs were incubated with peptides (ﬁnal concentration
of 10 µM) for 7 hours. The TILs were analysed with FACS Canto II
(BD Bioscience).
HLA tetramer staining and cell sorting
Tetramers coupled with PE and APC were prepared in-house, as
described previously.23 REP-TILs were stained with CD8-PerCP,
CD4-FITC (both BD Bioscience), NIR and the HLA tetramer complex
HLA-A3/GAGE-peptide conjugated with PE/APC. Tetramer-positive
cells were sorted using FACS Aria (BD Bioscience, New Jersey,
United States) and immediately expanded with allogeneic
irradiated PBMCs, human serum and IL-2 (two consecutive REP
procedures at smaller scale were carried out). In addition, GAGE-
speciﬁc clones were prepared by sorting one cell/well in a round
bottom 96-well plate containing allogeneic irradiated PBMCs,
human serum and IL-2 as described above.
RESULTS
Processing of specimens, initial TIL outgrowth and TCL generation
Characteristics of the clinical specimens are reported in Table 1. All
patients included in this study had histologically conﬁrmed OC,
the vast majority at an advanced disease stage (FIGO III or IV).
Various ovarian tumour histologies were represented, including
rare carcinosarcomas. Supplementary Figure 1A illustrates the
distribution of histologic subtypes in this cohort (n= 33).
At our centre, we have considerable experience in manufactur-
ing of TILs from MM,19,24 head and neck cancer25 and primary
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renal cell carcinoma (pRCC).26 In general, resected tumour
specimens, from MM and pRCC, contains a well-deﬁned area with
tumour tissue which can easily be dissected from surrounding
healthy tissues. In this study, all samples from OC were obtained
from intraperitoneal metastases. In contrast to melanoma and
pRCC, these samples were highly heterogeneous, typically more
difﬁcult to dissect from surrounding healthy tissues and in some
cases heavily inﬁltrated with mucinous areas (data not shown).
Young TIL cultures were successfully established from all samples
within 60 days (median 28 days, range [15–59]).
Autologous TCLs were established from 11 out of the 34 OC
specimens, including from subtypes such as serous adenocarci-
noma, carcinosarcoma and clear cell adenocarcinoma. TCLs were
established most successfully from transport media (7/34 cases).
Establishment of TCLs from fragments and ascites were successful
in 3/34 and 1/11 cases, respectively. From one patient TCLs were
established from both the fragments and the transport media. The
distribution of the subtypes of these TCLs is illustrated in
Supplementary Figure 1B.
Massive expansion (rapid expansion) of TILs
The REP is currently used in clinical trials of adoptive cell transfer
(ACT) to obtain large numbers of autologous TILs for intravenous
infusion.
All Young TIL cultures were further expanded with a median
fold expansion of more than 1500-fold (median 1660, range
[440–5544); Fig. 1a). Growth kinetics and fold expansions were
compared head-to-head to MM (n= 11). Median fold expansion in
MM-TIL appeared higher, median 2842 (range [816–6900]; p=
0.09 compared to OC-TIL); however, the difference was not
statistically signiﬁcant (Fig. 1b). In addition, a comparison of the
fold expansion of TILs from chemotherapy naïve patients (n= 20)
and TILs from patients treated with chemotherapy (n= 14)
showed no signiﬁcant difference (data not shown).
Phenotype of TILs
Young TILs contained mainly CD3+ cells (median 94.2%, range
[77.4–98.2], Fig. 2a), with a larger proportion of CD4+ T cells than
CD8+ T cells. A low frequency of NK cells (deﬁned as CD3−CD56+
lymphocytes) was detected in most patients (median 3.3% of
lymphocytes, range [0.3–18.2]; Fig. 2b). In addition, we also found
a small proportion of γδ T cells (median 1.5%, range [0.1–47.4]
(Fig. 2c).
The CD4/CD8 ratio was highly variable among all 33 individual
patients (median 7.2, range [0.01–306]; Figs. 2d, e). Most CD4+ and
CD8+ T cells displayed a phenotype consistent with experienced
effector memory T cells (Tem; CD45RO+CCR7−CD62L−), as deﬁned
by Sallusto et al.27
REP-TILs contained almost exclusively CD3+ T cells, with a
slightly higher CD4/CD8 ratio (10, range [0.02–1067], p= 0.07 vs
Young TILs, Fig. 2d). After REP, the fraction of CD8+ Tem cells
increased (p= 0.0004) along with a reduced fraction of Naïve
CD8+ T cells (p < 0.0001). The same pattern was observed in the
CD4+ T cell subpopulation Tem cells increased (p= 0.0003) along
with a reduced fraction of Naïve T cells (p < 0.0001)) (Figs. 2f, g).
Regarding the classic exhaustion markers, a decrease in the
PD-1+ cells was observed in both the CD8+ and CD4+
subpopulations after REP (p= 0.0002 and p < 0.0001, respectively).
A relative high fraction of LAG-3+ CD8+ CD4+ TILs were observed,
Young TILs CD8+ and CD4+ median 88.5% range [65.5–99.3] and
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Fig. 1 Ovarian tumour-inﬁltrating lymphocytes (TILs). Young TILs were further expanded using a small scale Rapid Expansion Protocol (REP).
a Fold expansion of TILs from 24 ovarian cancer (OC) patients (purple lines) and from 11 metastatic melanoma (MM) patients (blue lines)
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Mann–Whitney test. Data are presented with the median
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median 73.7% range [45.6–96.6], respectively, and REP-TILs CD8+
and CD4+ median range and median range, respectively. Mean-
while, a signiﬁcant increase of the LAG-3+ CD8+ subpopulation
after REP was observed (p= 0.0263) (Figs. 2h, i). In addition, the
expression of three markers, CD69, CD137 and CD28 was
determined (Supplementary Figure 2A and 2B).
In order to determine whether TILs were truly expanded from
the TME, the characteristics of the immune inﬁltrate in situ was
further analysed and compared to expanded TILs from ﬁve
specimens. Analysis of immune inﬁltrates in situ showed high
inter-patient variations (representative examples see Supple-
mentary Figure 3). The distribution of the four immune markers
analysed (CD4, CD8, CD20 and CD56) is illustrated in Supple-
mentary Figure 4A. The distribution of the four immune markers
was similar in FTD (Supplementary Figure 4A). The distribution
of CD4+ and CD8+ T cells in the TME (IHC data) was compared
to the distribution of the expanded CD4+ and CD8+ TILs from
the same specimens (Supplementary Figure 4B). In TILs from
each individual specimen, it appeared that similar CD4 to CD8
ratios were maintained throughout TIL expansion, with a
tendency of an increase in CD4+ T cells (Supplementary
Figure 4B). Overall, these data suggest that TILs are indeed
expanded from the TME of OC and not from surrounding
healthy tissues.
Tumour reactivity
The antitumour activity of the in vitro-expanded TILs was
evaluated after co-culture of TILs and either autologous FTD or
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TCLs. Responses of CD8+ T cells towards autologous TCLs were
detected in 7 of 11 patients, the median frequency in responders
1.4%, range [0.51–7.8]. Responses towards autologous TCLs
pretreated with IFN-γ were detected in 5 of 11 patients, median
frequency in responders 3.2%, range [2.1–8.8]. Antitumour
responses of CD8+ T cells to autologous FTD was observed in 8
of 30 patients tested, and the median frequency in responders
was 1.7%, range [0.6–3.4]. In total, CD8+ T cell responses against
autologous tumour cells were detected in 13 out of 31 patients
tested, with a median frequency of 3.05% (considering only the
highest value, when different assays were available for one
individual patient) (Fig. 3).
Fig. 2 Phenotypic characterisation of ovarian cancer TILs. Young TILs and REP-TILs were analysed with ﬂow cytometry for phenotypic markers.
a Scatterplot showing percentages of CD3+ T cells in Young TIL (n= 34) and REP TIL (n= 33) populations. Data are presented with the median.
b Scatterplot showing the percentage of NK cells in the Young TIL population (n= 34). Data are presented with the median. c Scatterplot
showing percentages of γδ T cells in Young TIL (n= 34) and REP TIL (n= 33) populations. Data are presented with the median. d Scatterplot
showing the CD4/CD8 ratios in Young TILs (n= 34) and REP-TILs (n= 33). The median CD4/CD8 ratio in Young TILs was 7.2 (range [0.01–306])
and 10.0 (range [0.02–1067]) in REP TIL population. Data were log-transformed before the two groups were compared. A signiﬁcant increase in
the ratio was observed (p= 0.0253). Data are presented with the median. e The pie charts show the phenotypic distribution of CD8+, CD4+,
CD4+CD8+ and CD4−CD8− of CD3+ TILs in the Young TIL (n= 34) and REP TIL (n= 33) populations. Data are presented with mean values. f,
g Scatterplots illustrating the percentage of naïve T cells, central memory T cells and effector memory T cells and h, i Scatterplots illustrating
the percentage of Exhaustion markers: LAG-3, BTLA, PD-1 and TIM-3 in f, h the CD8+ T cell population and g, i the CD4+ T cell population in
Young TILs (n= 34) and REP-TILs (n= 33). Data are presented with the median with interquartile range. Panel f shows a signiﬁcant increase of
CD8+ Tem cells p= 0.0004 during the REP and a signiﬁcant decrease in the Naïve T cell subpopulation, p < 0.0001. g The CD4-expressing
population had a signiﬁcant increase in CD4+ Tem cells during the REP, p= 0.0003, and a signiﬁcant decrease in the Naïve T cell subpopulation
during the REP, p < 0.0001. Panel h shows signiﬁcant increase of CD8+ LAG-3+ T cells p= 0.0263 during the REP and a signiﬁcant decrease in
the PD-1+ T cells, p= 0.0002, and a signiﬁcant increase in the TIM-3+ T cells, p= 0.0379. i The CD4-expressing population had a signiﬁcant
decrease in CD4+ BTLA+ cells during the REP, p= 0.013, and a signiﬁcant decrease in the PD-1+ T cell subpopulation during the REP, p <
0.0001. Young TILs and REP-TILs were compared using the Wilcoxon signed rank test. Statistical signiﬁcant differences is indicated with *, **,
*** or **** for p values less than 0.05, 0.01, 0.001, or 0.0001, respectively
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Fig. 3 In vitro antitumour activity of CD8+ Young TILs. The antitumour activity of the in vitro-expanded TILs was evaluated by deﬁning the
frequency of T cells expressing at least one of the following T cell functions: TNF-α, IFN-γ or CD107a, upon stimulation with autologous Fresh
tumour digest (FTD) or tumour cell line (TCL) treated with low-dose IFN-γ (100 IU/ml) or left untreated. A speciﬁc antitumour response was
deﬁned as the presence of minimum 0.5% responding cells, with a minimum number of 50 positive events. The frequency of tumour-reactive
cells in stimulated samples was subtracted from the unstimulated samples. In all, 0.5% was used as a threshold for detection of tumour
reactivity. a Antitumour responses of CD8+ T cells were detected in 13 of 31 patients analysed. *: OC.TIL.03 is not tested with FTD. ϕ: TILs
generated from OC.TIL.04 2nd was tested for reactivity against FTD from OC.TIL.04. b FACS plot showing cytokine production from TIL alone
(unstimulated, serving as a negative control) and TIL stimulated with autologous TCL, from a representative patient (OC.TIL.11). c FACS plot
showing CD107a mobilisation of TIL upon co-culture with an autologous TCL. Unstimulated TIL (TIL alone) serves as a negative control. An
example of the gating strategy is showed in Supplementary Figure 7A
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Responses of CD4+ T cells to autologous TCLs were only
detected when the TCL had been pretreated with IFN-γ and in this
case, a response of 1.6% of the CD4+ T cells was only detected in 1
of 11 patients (OC.TIL.07; 9%). Six selected TCLs (OC.TIL.03, -04, -07,
-09, -11, -33) were analysed for HLA class I and HLA class II
expression. All TCLs expressed constitutively HLA class I. None of
the TCL expressed HLA class II constitutively, but treatment with
IFN-γ induced high or moderate HLA class II expression in three
cell lines (OC.TIL.07, -09, -33; Supplementary Figure 5). Antitumour
responses of CD4+ T cells to autologous FTD were detected in 15
of 30 patients (50%), median frequency in responders 3.3%, range
[0.8–7.3]. In total, CD4+ T cell responses to autologous tumour
cells were detected in 16 out of 31 patients tested (52%), with a
median frequency of 3.3% (considering only the highest value,
when different assays were available for one individual patient)
(Fig. 4).
Overall, antitumour T cell responses (either CD8+ or CD4+
T cells) were detected in 19 of 31 patients tested (61%)
We observed an NK cell antitumour response in 8 of 29 patients.
Although the median frequency of responding NK cells was
generally low (1.45%), occasionally a high fraction of NK cells
recognised autologous TCLs (Supplementary Figure 6). The NK cell
antitumour responses were found in both TILs with and without
an in vitro antitumour T cell response (data not shown).
We determined whether TILs from selected patients with OC
had cytolytic activity to autologous tumours. Young TILs from
patient OC.TIL.11 generated highly speciﬁc lysis of the autologous
tumour cells; however, the cytotoxic potential of the TILs
decreased after the TILs have been rapid expanded (Supplemen-
tary Figure 7A). Young TILs from patient OC.TIL.04 also generated
speciﬁc lysis of the autologous tumour cells, whereas lysis capacity
disappeared after REP (Supplementary Figure 7B). For patient OC.
TIL.11, the cytolytic potential of TILs was conﬁrmed with another
assay (xCELLigence assay), where the T cell-tumour interplay can
be studied in real time for a prolonged period. A clear correlation
between the number of effector cells per target cells and the
duration of time before complete tumour elimination was
observed (Supplementary Figure 7C).
Identiﬁcation of immunogenic antigens presented on OC cells
One OC cell line (OC.TIL.11) was analysed with LC-MS-based
immunopeptidomics and multiple tumour-associated antigens
were identiﬁed. The immunogenicity of these peptides was
determined using the IFN-γ ELISPOT assay. We identiﬁed two
overlapping peptides of the GAGE cancer-testis antigen family
STYYWPRPR and YYWPRPRRY eliciting a clear IFN-γ response (119
and 47 spots, respectively) in patient OC.TIL.11 (Fig. 5). The
responses in OC.TIL.11 were conﬁrmed with ICS and ﬂow
cytometry analysis (Supplementary Figure 8).
GAGE-speciﬁc TILs were sorted using tetramer complexes of
HLA-A3/STYYWPRPR and further expanded with two consecutive
REPs. This procedure resulted in one T cell culture highly enriched
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Fig. 4 In vitro antitumour activity of CD4+ Young TILs. The antitumour activity of the in vitro-expanded TILs was evaluated by deﬁning the
frequency of T cells expressing at least one of the following T cell functions: TNF-α, IFN-γ or CD107a, upon stimulation with autologous fresh
tumour digest (FTD) or tumour cell line (TCL) treated with low-dose IFN-γ (100 IU/ml) or left untreated. A speciﬁc antitumour response was
deﬁned as the presence of minimum 0.5% responding cells, with a minimum number of 50 positive events. The frequency of tumour-reactive
cells in stimulated samples was subtracted from unstimulated samples; 0.5% was used as a threshold for detection of tumour reactivity.
a Antitumour responses of CD4+ T cells were detected in 16 of 31 patients. *OC.TIL.03 is not tested with FTD. ϕ: TILs generated from OC.TIL.04
2nd was tested for reactivity against FTD from OC.TIL.04. b FACS plot showing cytokine production from TIL alone (unstimulated, serving as a
negative control) and TIL stimulated with autologous TCL, from a representative patient (OC.TIL.15). An example of the gating strategy is
showed in Supplementary Figure 7A
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with GAGE-speciﬁc T cells (around 90% stained positive for the
HLA-A3/STYYWPRPR-tetramer). This GAGE-speciﬁc T cell-enriched
culture displayed a very high recognition of both the GAGE-
peptide STYYWPRPR and autologous TCL (Fig. 6). Furthermore, the
GAGE-speciﬁc culture’s ability to kill autologous tumour cells was
conﬁrmed with the xCelligence assay. The addition of HLA class I
and HLA class II antibodies further conﬁrmed that the response is
HLA class I dependent (Fig. 6c). Similar high immune recognition
was observed with one GAGE-speciﬁc clone obtained from the
same original TILs (Supplementary Figure 9).
DISCUSSION
Recent successes of ACT with TILs in MM warrant investigating this
treatment strategy in other cancer types. Until recent years,
current TIL manufacturing methods had not been applied to other
immunogenic solid tumours such as OC.
In this study, TILs from all patients were expanded to sufﬁcient
numbers for clinical application. OC-TILs displayed growth proper-
ties similar to those of MM-TILs. We expanded TILs from MM
specimens to reach 100 × 109 cells (5000 fold expansion) for
infusion28 and clinical responses were achieved in over 40% of
treated patients.24
We investigated the phenotype of the TILs before and after the
REP with a broad panel of surface markers and found an
abundance of effector memory T cells. This is consistent with
phenotype analyses performed in other solid tumours, e.g., MM.19
The distribution of major T cell subpopulations, including CD4+
and CD8+ T cells, did not change dramatically during the REP. In
general, we found a higher frequency of CD4+ T cells than CD8+
T cells in the expanded OC-TIL products, which was also true in
the original TME. This ﬁnding differs from previous observations in
the majority of melanomas.29 In addition, we observed a relatively
high expression of the exhaustion marker LAG-3 in the TILs, which
could be induced by high concentration of IL-2 in the culture
medium and it could be a piece in the puzzle of the low
antitumour reactivity in TILs.
A recent study by the Brad Nelson group30 showed that OC
patients receiving neoadjuvant chemotherapy had tumour tissue
with increased densities of CD3+ and CD8+ T cells compared to
chemotherapy naïve tumour tissue using IHC analysis. The tumour
specimens in our study included 20 chemotherapy naïve speci-
mens and 14 specimens from patients who received chemother-
apy prior to the tumour resection. Our preliminary analysis of
these two groups did not show dramatic differences in TIL
expansion or phenotype (data not shown).
Current methods of TIL isolation require dissection of viable
tumours from surrounding tissues. This is typically achieved by
scalpel separation of the tumour tissue from the healthy tissue.
Our experience and macroscopic characteristics of most OC
tumours indicate that the scalpel separation technique is more
difﬁcult to apply on OC tumours than MM. It is of great importance
that the lymphocytes are expanded from the TME and not from
healthy tissue. By comparing the composition of in situ tumour
inﬁltrates and expanded TILs, we provide indirect evidence that
the TILs in our study were truly expanded from the TME.
Most importantly, we showed that tumour-reactive TILs could
be recovered from the TME in the majority of patients with
unselected histologies of OC. This observation resembles the
ﬁndings in melanoma31,32 and other solid cancer types such as
head and neck squamous cell carcinoma,25 metastatic gastro-
intestinal adenocarcinomas,33 and RCC.26,34,35 However, it
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appeared that the frequency of tumour-reactive T cells in OC-TILs
was lower than reported in MM-TILs.20 A very recent study in OC
with a slightly different manufacturing approach showed similar
results as present ﬁndings, though with a markedly lower TIL
expansion rate.36
In-depth phenotypic characterisation of immune responses
showed that tumour-reactive CD4+ T cells frequently inﬁltrate OC.
In one patient, we conﬁrmed the direct recognition of autologous
tumour cells by tumour-speciﬁc CD4+ T cells. In addition, we
observed signiﬁcantly more CD4+ T cell responses after co-culture
with FTD than when using autologous TCLs. This can potentially
be explained by the additional presence of antigen-presenting
cells in the FTD, which can activate CD4+ T cells and thereby elicit
greater immune responses compared to autologous TCLs. We and
others have previously shown that CD4+ T cells can recognise
autologous tumour, including mutant neo-antigens, presented
directly by MM tumour cells.20,37,38 Based on these current
ﬁndings, it appears that CD4+ T cells also play a role in the
surveillance of the TME of OC.
Finally, we identiﬁed using advanced MS-based immunopepti-
domics analysis tumour antigens directly presented on the tumour
cells. We conﬁrmed that two cancer-testis antigens from the GAGE
family elicited T cell responses in vitro in one OC patient. The
immunogenicity of one of these peptides (YYWPRPRRY) has
already been reported previously.39 However, for the ﬁrst time to
our knowledge, GAGE-speciﬁc TILs to HLA peptide STYYWPRPR
were successfully isolated and expanded. These ﬁndings are in-
line with a recent study showing the presence of neo-epitope
speciﬁc CD8+ TILs from OC.40 This speciﬁc population displayed a
profound increase in the T cell recognition of the autologous
tumour cells. However, Wick et al.8 showed that despite successful
T cell recognition of neo-antigens in OC, this might not necessarily
prevent tumour progression. The same group recently showed
that the expression of neo-antigens in OCs is deﬁcient compared
to other cancer types. They only found a few neo-antigen-speciﬁc
CD4+ and CD8+ T cell responses in vitro and none in vivo using
neo-antigen-speciﬁc vaccines. OC is mostly driven by large-scale
mutations, and current bioinformatic prediction tools may not be
able to predict which neo-antigens are presented in OC.41
Additional methods, such as LC-MS-based immunopeptidomics,
may provide additional insights into the antigen repertoire of
OC.42
In conclusion, we show that TILs can efﬁciently be expanded
from OC. However, unselected TILs from OC generally contain
small amounts of tumour-reactive T cells. One of the limiting
factors could be the ability to enrich for tumour-reactive T cells,
which can be achieved using novel technologies.9,40,43 These data
encourage further studies to test the efﬁcacy of ACT in OC and
highlight the need for improved methods of manufacturing to
increase the quality of TIL products.
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